Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Bright, Richard J ^a,b,c   Wilkinson, Jenny ^b   Coventry, Brendon J ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Anti myelin associated glycoprotein; Autoimmune diseases; Chronic inflammatory demyelinating polyneuropathy; Corticosteroids; IVIg; Peripheral neuropathy; Plasmapheresis; Treatment

Indexed keywords

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893665881     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-26     Document Type: Article

References (40)

1. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006, 11(1):30-46. 10.1111/j.1085-9489.2006.00061.x, 16519780.
2. Dalakas MC. Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. J Peripher Nerv Syst 2012, 17(Suppl 2):34-39.
3. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011, 7(9):507-517. 10.1038/nrneurol.2011.121, 21844897.
4. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005, 352(13):1343-1356. 10.1056/NEJMra041347, 15800230.
5. Said G. Chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord 2006, 16(5):293-303. 10.1016/j.nmd.2006.02.008, 16631367.
6. Anthoney DA, Bone I, Evans TR. Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2000, 11(9):1197-1200.
7. Bird SJ, Brown MJ, Shy ME, Scherer SS. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 1996, 46(3):822-824. 10.1212/WNL.46.3.822, 8618691.
8. Briemberg HR, Amato AA. Inflammatory neuropathies. Curr Neurol Neurosci Rep 2005, 5(1):66-71. 10.1007/s11910-005-0026-z, 15676111.
9. Zeng XL, Nagavalli A, Smith CJ, Howard JF, Su MA. Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency. Journal of immunology 2013, 190(8):3895-3904.
10. van Schaik IN, Vermeulen M, van Doorn PA, Brand A. Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg). J Neuroimmunol 1994, 54(1-2):109-115.
11. Feeney DJ, Pollard JD, McLeod JG, Stewart GJ, Doran TJ. HLA antigens in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1990, 53(2):170-172. 10.1136/jnnp.53.2.170, 487961, 2313306.
12. van Doorn PA, Schreuder GM, Vermeulen M, D'Amaro J, Brand A. HLA antigens in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1991, 32(2):133-139. 10.1016/0165-5728(91)90005-R, 1849516.
13. Czaplinski A, Steck AJ. Immune mediated neuropathies-an update on therapeutic strategies. J Neurol 2004, 251(2):127-137. 10.1007/s00415-004-0323-5, 14991345.
14. Kuitwaard K, van Doorn PA. Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 2009, 69(8):987-1001. 10.2165/00003495-200969080-00004, 19496628.
15. van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review. Lancet Neurol 2002, 1(8):491-498. 10.1016/S1474-4422(02)00222-3, 12849334.
16. Yoon MS, Chan A, Gold R. Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Ther Adv Neurol Disord 2011, 4(3):193-200. 10.1177/1756285611405564, 3105635, 21694819.
17. Robertson EE, Donofrio PD. Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2010, 12(2):84-94. 10.1007/s11940-010-0058-9, 20842572.
18. Group RMCT. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 2009, 8(2):158-164.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
20. Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2010, 74(8):651-657. 10.1212/WNL.0b013e3181d1a862, 20177118.
21. Hermans G, Clerckx B, Vanhullebusch T, Segers J, Vanpee G, Robbeets C, Casaer MP, Wouters P, Gosselink R, Van Den Berghe G. Interobserver agreement of Medical Research Council sum-score and handgrip strength in the intensive care unit. Muscle Nerve 2012, 45(1):18-25. 10.1002/mus.22219, 22190301.
22. Zinman LH, Sutton D, Ng E, Nwe P, Ngo M, Bril V. A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci 2005, 33(3):317-324. 10.1016/j.transci.2005.07.010, 16239123.
23. Bril V, Tomioka S, Buchanan RA, Perkins BA. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabetic medicine: a journal of the British Diabetic Association 2009, 26(3):240-246. 10.1111/j.1464-5491.2009.02667.x, 2871179, 19317818.
24. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001, 124(Pt 1):145-153.
25. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993, 56(1):36-39. 10.1136/jnnp.56.1.36, 1014761, 8429321.
26. Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke; a journal of cerebral circulation 1989, 20(6):828. 10.1161/01.STR.20.6.828, 2728057.
27. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 2010, 67(7):802-807. 10.1001/archneurol.2010.105, 20457948.
28. Merkies IS, Schmitz PI. Getting closer to patients: the INCAT overall disability sum score relates better to patients' own clinical judgement in immune-mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2006, 77(8):970-972. 10.1136/jnnp.2005.076174, 2077640, 16549419.
29. Kuitwaard K, van den Berg LH, Vermeulen M, Brusse E, Cats EA, van der Kooi AJ, Notermans NC, van der Pol WL, van Schaik IN, van Nes SI, et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2010, 81(12):1374-1379. 10.1136/jnnp.2010.206599, 20587484.
30. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(25):2572-2581. 10.1056/NEJMoa032534, 15201414.
31. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009, 65(3):286-293. 10.1002/ana.21577, 19334068.
32. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012, 78(14):1079-1084. 10.1212/WNL.0b013e31824e8f84, 22442436.
33. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead mobility index: a further development of the Rivermead motor assessment. International disability studies 1991, 13(2):50-54. 10.3109/03790799109166684, 1836787.
34. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9(3):245-253. 10.1016/S1474-4422(10)70021-1, 20133204.
35. Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004, 3. CD003906.
36. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986, 314(8):461-465. 10.1056/NEJM198602203140801, 3511382.
37. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119(4):1055-1066. 10.1093/brain/119.4.1055, 8813270.
38. Lam J, Wulff H. The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression. Drug development research 2011, 72(7):573-584. 10.1002/ddr.20467, 3253536, 22241939.
39. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. The voltage-gated Kv1.3 K + channel in effector memory T cells as new target for MS. J Clin Invest 2003, 111(11):1703-1713. 10.1172/JCI16921, 156104, 12782673.
40. Remenyi P, Masszi T, Borbenyi Z, Soos J, Siklos L, Engelhardt JI. CIDP cured by allogeneic hematopoietic stem cell transplantation. Eur J Neurol 2007, 14(8):e1-e2.